Brady Huggett

Maxygen Inc. signed a deal with F. Hoffmann-La Roche Ltd. focused on Maxygen's interferon alpha and beta variants portfolio. At this point, Roche has rights to candidates for hepatitis B and C, but if it takes its option on other indications, the deal's value could blossom to more than $230 million. (BioWorld Today)

Maxygen Signs Interferon Deal With Roche Worth Up To $230M

May 23, 2003

By Brady Huggett

Maxygen Inc. signed a deal with F. Hoffmann-La Roche Ltd. focused on Maxygen's interferon alpha and beta variants portfolio. At this point, Roche has rights to candidates for hepatitis B and C, but if it takes its option on other indications, the deal's value could blossom to more than $230 million. (BioWorld Today)

Connetics Seeking $75M Through Notes Sale As It Nears Profitability

May 22, 2003

By Brady Huggett

Brady Huggett

ARTICLES

LSE Rule Change Meant To Spark More Foreign Listings In London

Awaiting Cialis Decision, ICOS Files $150M Shelf Registration

Awaiting Cialis Decision, ICOS Files $150M Shelf Registration

Peninsula In-Licenses Late-Stage Antibiotic From Japanese Firm

Peninsula In-Licenses Late-Stage Antibiotic From Japanese Firm

BioMS Plans Pivotal Trial Talks On MBP8289 Phase II MS Results

BioMS Plans Pivotal Trial Talks On MBP8289 Phase II MS Results

Maxygen Signs Interferon Deal With Roche Worth Up To $230M

Maxygen Signs Interferon Deal With Roche Worth Up To $230M

Connetics Seeking $75M Through Notes Sale As It Nears Profitability

Today's news in brief

Today's news in brief

ADCs’ breakout 2025 and their still-unfinished potential

LINC01116 has prognostic value in lung cancer, study shows

ADCs’ breakout 2025 and their still-unfinished potential